Literature DB >> 34934570

Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis.

Gyusik Park1, Hassan Kesserwani2.   

Abstract

Autoimmune myasthenia gravis (MG) is a well-characterized post-synaptic disorder of neuromuscular transmission. Immunologically, there is complement activation with autoantibodies binding to the acetylcholine receptor (AChR), leading to cross-linking and internalization of the receptor. The diminished functional clustering leads to impaired folding of the post-synaptic membrane. The antibodies generated by the autoimmune process are directed at the various components of the post-synaptic membrane and its scaffolding, including the AChR, muscle-specific tyrosine kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), and the other recently described epitopes including the extracellular membrane proteins agrin and collagen Q (ColQ). MuSK MG is phenotypically different from classic AChR-antibody-mediated MG by a more frequent presentation of bulbar weakness, less responsiveness to symptomatic therapy with acetylcholinesterase inhibitors, the absence of a thymoma, and a better therapeutic response to a cluster of differentiation (CD-20) B-cell therapy such as rituximab. The pleiotropic ocular findings of ocular MG include ptosis, fluctuating and variable involvement of cranial nerves III, IV, and VI, pseudo-internuclear ophthalmoplegia (INO), near-complete or complete ophthalmoplegia, and variable gaze palsies. To our knowledge, we present one of the very few reported cases of MuSK MG presenting as isolated sixth nerve palsy. The localization of a sixth nerve palsy with lateral rectus muscle weakness can be due to disease anywhere along its path from the abducens nucleus, coursing at the skull base through Dorello's canal, through the cavernous sinus, and along its path through the superior orbital fissure and into the orbits. A painless sixth nerve palsy should alert the clinician to MuSK-MG as we outline in this case report.
Copyright © 2021, Park et al.

Entities:  

Keywords:  abducens nerve palsy; autoimmune disease; horizontal diplopia; muscle-specific tyrosine kinase; musk myasthenia gravis; neuromuscular junction; ocular myasthenia gravis

Year:  2021        PMID: 34934570      PMCID: PMC8684330          DOI: 10.7759/cureus.19701

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  12 in total

Review 1.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

2.  Long-lasting treatment effect of rituximab in MuSK myasthenia.

Authors:  J Díaz-Manera; E Martínez-Hernández; L Querol; R Klooster; R Rojas-García; X Suárez-Calvet; J L Muñoz-Blanco; C Mazia; K R Straasheijm; E Gallardo; C Juárez; J J Verschuuren; I Illa
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

3.  Myasthenia gravis presenting as a unilateral abducens nerve palsy.

Authors:  H Feuer; A Jagoda
Journal:  Am J Emerg Med       Date:  2001-09       Impact factor: 2.469

Review 4.  Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.

Authors:  John Morren; Yuebing Li
Journal:  Muscle Nerve       Date:  2018-03-25       Impact factor: 3.217

Review 5.  Myasthenia gravis: subgroup classification and therapeutic strategies.

Authors:  Nils Erik Gilhus; Jan J Verschuuren
Journal:  Lancet Neurol       Date:  2015-10       Impact factor: 44.182

Review 6.  Myasthenia gravis with antibodies to MuSK: an update.

Authors:  Amelia Evoli; Paolo E Alboini; Valentina Damato; Raffaele Iorio; Carlo Provenzano; Emanuela Bartoccioni; Mariapaola Marino
Journal:  Ann N Y Acad Sci       Date:  2017-12-21       Impact factor: 5.691

7.  A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.

Authors:  P Zisimopoulou; P Evangelakou; J Tzartos; K Lazaridis; V Zouvelou; R Mantegazza; C Antozzi; F Andreetta; A Evoli; F Deymeer; G Saruhan-Direskeneli; H Durmus; T Brenner; A Vaknin; S Berrih-Aknin; M Frenkian Cuvelier; T Stojkovic; M DeBaets; M Losen; P Martinez-Martinez; K A Kleopa; E Zamba-Papanicolaou; T Kyriakides; A Kostera-Pruszczyk; P Szczudlik; B Szyluk; D Lavrnic; I Basta; S Peric; C Tallaksen; A Maniaol; S J Tzartos
Journal:  J Autoimmun       Date:  2013-12-24       Impact factor: 7.094

Review 8.  Ocular myasthenia gravis: a review.

Authors:  Akshay Gopinathan Nair; Preeti Patil-Chhablani; Devendra V Venkatramani; Rashmin Anilkumar Gandhi
Journal:  Indian J Ophthalmol       Date:  2014-10       Impact factor: 1.848

9.  IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG.

Authors:  Saif Huda; Patrick Waters; Mark Woodhall; Maria Isabel Leite; Leslie Jacobson; Anna De Rosa; Michelangelo Maestri; Roberta Ricciardi; Jeannine M Heckmann; Angelina Maniaol; Amelia Evoli; Judy Cossins; David Hilton-Jones; Angela Vincent
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.